Adnet P, Krivosic-Horber R
Département d'Anesthésie-Réanimation Chirurgicale I, Hôpital B, Centre Hospitalier Universitaire, Lille.
Ann Fr Anesth Reanim. 1988;7(6):494-505. doi: 10.1016/s0750-7658(88)80088-1.
Calcium blockers (CB) are routinely used. This could lead to possible interference with anaesthetic drugs. CB prevent calcium from entering the cell by inhibiting the slow voltage-dependent calcium channels. They act mostly on heart and smooth muscle. Of all the possible indications, the three that are confirmed are coronary heart disease, arterial hypertension and supraventricular rhythm disturbances. Most of the work published and the cases reported concerns interactions between CB and halogenated anaesthetic agents; the latter's actions on the heart depend on cellular calcium exchange. Also, the cardiovascular effects of these anaesthetics are similar to that of CB. Experimentally, halothane and enflurane have direct cardiac inhibitory effects similar to verapamil and diltiazem, whereas isoflurane's properties seem closer to the dihydropyridines (nifedipine and nicardipine). Giving verapamil or diltiazem increases the number of sino-atrial and atrio-ventricular blocks when using a halogenated agent. Clinically, interpreting the effects of CB during anaesthetic induction is difficult because of the pathology (coronary heart disease, cardiac failure), the other drugs (beta-blockers and nitrates) and the type of anaesthesia (emergency or elective). Interactions can give rise to anything from a severe cardiovascular collapse, requiring catecholamines, to a mild fall in blood pressure which responds well to plasma expansion, or even no effect on blood pressure. Rebound is seen on stopping CB in patients with coronary heart disease or arterial hypertension; stopping them before surgery does not therefore seem justified. However, extreme care must be taken when using halogenated agents for patients under treatment with CB and/or beta-blockers. A wary anaesthetist will be able to adapt the technique to the patient. It has been suggested that CB could be used to treat preoperatively myocardial ischaemia (diltiazem), hypertensive crises (nifedipine, nicardipine) and ventricular rhythm disturbances (verapamil); this must be done with caution, the patient being closely monitored (haemodynamic and electrocardiographic monitoring). Postoperatively, intranasal nifedipine, continuous intravenous nicardipine or diltiazem have been used to treat increases in arterial blood pressure during recovery and to adapt the cardiovascular system to the increased metabolic needs. Here again, close patient monitoring is essential. In any case, treatment with CB which has been stopped should be started up again as soon as possible.
钙通道阻滞剂(CB)被常规使用。这可能会导致与麻醉药物产生潜在相互作用。CB通过抑制电压依赖性慢钙通道来阻止钙进入细胞。它们主要作用于心脏和平滑肌。在所有可能的适应症中,已得到确认的三种是冠心病、动脉高血压和室上性心律失常。已发表的大多数研究和报告的病例都涉及CB与卤化麻醉剂之间的相互作用;后者对心脏的作用取决于细胞钙交换。此外,这些麻醉剂的心血管效应与CB相似。实验表明,氟烷和恩氟烷具有与维拉帕米和地尔硫卓相似的直接心脏抑制作用,而异氟烷的特性似乎更接近二氢吡啶类药物(硝苯地平和尼卡地平)。使用卤化麻醉剂时,给予维拉帕米或地尔硫卓会增加窦性和房室传导阻滞的发生率。在临床上,由于患者的病理状况(冠心病、心力衰竭)、其他药物(β受体阻滞剂和硝酸盐)以及麻醉类型(急诊或择期),在麻醉诱导期间解读CB的作用很困难。相互作用可能导致从严重的心血管崩溃(需要使用儿茶酚胺)到轻度血压下降(对扩容治疗反应良好),甚至对血压没有影响等各种情况。在冠心病或动脉高血压患者停用CB时会出现反跳现象;因此,在手术前停用它们似乎没有道理。然而,对于正在接受CB和/或β受体阻滞剂治疗的患者使用卤化麻醉剂时必须格外小心。谨慎的麻醉医生能够根据患者情况调整技术。有人建议CB可用于术前治疗心肌缺血(地尔硫卓)、高血压危象(硝苯地平、尼卡地平)和室性心律失常(维拉帕米);但必须谨慎进行,密切监测患者(进行血流动力学和心电图监测)。术后,鼻内给予硝苯地平、持续静脉输注尼卡地平或地尔硫卓已被用于治疗恢复期间的动脉血压升高,并使心血管系统适应增加的代谢需求。同样,密切监测患者至关重要。无论如何,已停用的CB治疗应尽快重新开始。